MASON, Ohio--(BUSINESS WIRE)--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial.
Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology at the Emory Heart and Vascular Center at Emory St. Joseph’s Hospital, a role he has served in since 2014. Dr. DeLurgio earned his medical degree from the University of California Los Angeles School of Medicine, and completed a fellowship in Cardiac Electrophysiology at Emory University School of Medicine. He originally joined Emory Healthcare in 1996 and served as Director of the Arrhythmia Center and Electrophysiology Lab at Emory University Hospital Midtown.
“I am honored and humbled to be given this opportunity to serve as the national PI for the CONVERGE trial,” said Dr. DeLurgio. “This landmark study is critically important research in the field of cardiac electrophysiology. At Emory, we have adopted the Convergent approach and have experienced first-hand the results of this therapy. Now, I’m looking forward to taking a leadership role and partnering with other trial sites to quickly enroll patients and complete the trial.”
The CONVERGE IDE trial is a landmark prospective, randomized trial comparing the Convergent approach to endocardial catheter ablation for patients with persistent or long-standing persistent Afib. The Convergent approach is a multi-disciplinary therapy in which a closed-chest epicardial ablation is performed by a surgeon, and then complemented by an endocardial catheter ablation performed by an electrophysiologist. In addition to the ongoing IDE trial, individual center results have been published in numerous peer reviewed papers.
“We are very excited about having Dr. DeLurgio serve in this role,” said Mike Carrel, AtriCure’s President and Chief Executive Officer. “Momentum in the CONVERGE trial continues to build as we add new sites and launch various patient recruitment initiatives. We are looking forward to building on this momentum with the leadership of Dr. DeLurgio.”
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005300/en/
